Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

ence of venous thromboembolism in the USA: now and future.

Thromb Haemost 2009;7 (Suppl. 2):207-8 (abstract OC-WE-018).

6.        Heit JA, Cohen AT, Anderson FAJ, on behalf of the VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. ASH Annual Meeting Abstracts. 106:910. 2005.

7.        Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Seminars in Thrombosis and Hemostasis. 2002;(s2):003– 014.

8.        Ogata, K et al. Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. J Clin Pharmacol. 2010;50:743-753.

9.        Ruff CT et al. Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; Oct;160(4):635-41.

10.     Daiichi Sankyo press release - Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery. 19 July 2011. Available at: http://www.daiichisankyo.com/news/detail/004123.html. [Last accessed: July 2013].

 


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 01, 2015 Research and Markets ( ... Dermatology Devices Market by Type, by End User - Forecast ... Asian Dermatology Devices market is estimated to grow at a ... holds a larger share in the Dermatology devices ... . The Asian Dermatology Devices market holds a high ...
(Date:5/1/2015)... Colo. , May 1, 2015   Heska Corporation ... or the "Company"), a provider of advanced veterinary diagnostic ... Robert Grieve , Executive Chair, will present at the 16th ... (PT), on May 13, 2015. The conference will be held ... Angeles, CA. Heska management will be available during ...
(Date:5/1/2015)... 2015  CytRx Corporation (CYTR), a biopharmaceutical research ... financial results for the three months ended March ... accomplishments and upcoming milestones for its clinical development ... the early months of 2015, including the announcement ... aldoxorubicin in patients with soft tissue sarcoma, and ...
Breaking Medicine Technology:Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 2Asian Dermatology Devices (Treatment & Diagnostic) Market by Type, by End User - Forecast to 2019 3Heska to Present at the 16th Annual B. Riley & Co. Investor Conference 2CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... , SAN DIEGO , Feb. 2 ADVENTRX ... Principal Executive Officer, Brian M. Culley , will present at the ... 2010 , at 10:30 a.m. Eastern time , in the Park ... conference is being hosted by the Biotechnology Industry Association. , Interested parties ...
... , , ... February 2 ReportsandReports announce to,have Biosimilars Series: Forecast ... The high cost and utilization of ... provides considerable momentum to,the emerging biosimilars market. With a biosimilar ...
Cached Medicine Technology:ADVENTRX Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference on February 9 2ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report 2ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report 3
(Date:5/2/2015)... On Tuesday April 7th, the patient care ... celebrate improvements in patient care. In 2014 the hospital, ... zero acquired ventilator associated infections, zero central line associated ... also recently named a Top Performer by the Joint ... the teamwork of staff from all departments involved in ...
(Date:5/2/2015)... 2015 As a nonsurgical staple ... the face, neck and décolleté, radiofrequency energy is ... potential for the success of vulvovaginal rejuvenation. In ... Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory Board ... that ThermiGyn’s temperature controlled radio frequency, specifically that ...
(Date:5/2/2015)... With the success that Veatch Dental Consulting has ... Neida Miranda and Alex Shields to the team. With Neida ... years of combined experience working with dentists to ensure their ... for 8 years. She was certified as dental assistant ... positive attitude and showing the importance of oral hygiene to ...
(Date:5/1/2015)... Islands, BWI (PRWEB) May 02, 2015 ... It is http://www.thevenetiangracebay.com , and it is ... incorporates the stunning white and attractive turquoise hues of ... of Google, sixty seven percent of leisure travelers used ... showed that smartphones were used in the planning and ...
(Date:5/1/2015)... Anaheim, CA (PRWEB) May 01, 2015 ... Ethos Award for the successful repositioning of its flagship ... its company brand with a new name, new logo, ... The DSA Ethos Awards are designed to identify and ... at its best. , “DSA congratulates Jusuru International ...
Breaking Medicine News(10 mins):Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5
... Presentation to highlight milestones including phase III development of ... What: Horizon Therapeutics, Inc. is pleased to announce that ... M.D., Ph.D., chief executive officer, will ... including its recent completion of Series C financing, and ...
... Twelve of Sixteen FH Patients in an Ongoing Open-Label Extension Study,Have Been Dosed With ... Four Have Been Dosed for More Than ... 8:00 a.m. E.T. ... at http://www.isispharm.com , CARLSBAD, Calif., Oct. 5 Isis,Pharmaceuticals, Inc. (Nasdaq: ...
... knows about the,FDA,s impending ban on children,s cold ... scramble to find other ways to alleviate their ... recently,introduced into the U.S. -- offers a safe ... According to the FDA, popular medicines such ...
... SOUTH SAN FRANCISCO, Calif., Oct. 4 Sunesis,Pharmaceuticals, Inc. ... inducement stock options awards in accordance with NASDAQ,Marketplace Rule ... stock options cover an aggregate of 48,000 shares of,common ... an,exercise price equal to the fair market value of ...
... U.S. may,be breathing its last gasps, as the ... Passage in the House is expected to be ... past six years, this legislation would,finally ban asbestos, ... asbestos, most deadly cancer, mesothelioma (meso), and other,asbestos-related ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the appointment ... Company,s new independent auditor effective October,2, 2007. BPM, ... the Audit Committee of the Company,s Board of ... with several,public accounting firms. BPM replaces PricewaterhouseCoopers LLP. ...
Cached Medicine News:Health News:Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 2Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 3Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 4Health News:Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months 5Health News:Nosefrida Nasal Aspirator - A Parent's Alternative to Medicines on the Verge of FDA Ban 2Health News:Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 2Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 3Health News:Asbestos No More: Historic Asbestos Ban Passage Imminent 4
Intermittent catheter...
Intermittent catheter...
... new Finnpipette Focus from Thermo Labsystems was ... performance. Advanced features such as the ... volume adjustment on microvolumes help to define ... channel pipettes. The new interchangeable handle plate ...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
Medicine Products: